Takakusagi, S.; Sato, K.; Marubashi, K.; Kizawa, K.; Kosone, T.; Kakizaki, S.; Takagi, H.; Uraoka, T.
Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines 2021, 9, 660.
https://doi.org/10.3390/biomedicines9060660
AMA Style
Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T.
Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines. 2021; 9(6):660.
https://doi.org/10.3390/biomedicines9060660
Chicago/Turabian Style
Takakusagi, Satoshi, Ken Sato, Kyoko Marubashi, Kazuko Kizawa, Takashi Kosone, Satoru Kakizaki, Hitoshi Takagi, and Toshio Uraoka.
2021. "Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C" Biomedicines 9, no. 6: 660.
https://doi.org/10.3390/biomedicines9060660
APA Style
Takakusagi, S., Sato, K., Marubashi, K., Kizawa, K., Kosone, T., Kakizaki, S., Takagi, H., & Uraoka, T.
(2021). Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines, 9(6), 660.
https://doi.org/10.3390/biomedicines9060660